Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a...

Area of Science:

• Oncology
• Medical Research

Background:

• High-dose ifosfamide (HD-IFO) is an established treatment for advanced bone and soft tissue sarcomas.
• Predictors for long-term patient benefit from HD-IFO therapy are not well-defined.

Purpose of the Study:

• To evaluate clinical outcomes and identify prognostic factors in sarcoma patients treated with HD-IFO.
• To utilize machine learning-assisted modeling for analyzing treatment effectiveness.

Main Methods:

• Retrospective analysis of 26 sarcoma patients treated with HD-IFO (≥12 g/m² per cycle).
• Progression-free survival (PFS) and overall survival (OS) analyzed using Kaplan-Meier and log-rank tests.
• Prognostic factors identified via LASSO logistic regression and multivariable analysis.

Main Results:

• Median PFS was 6.6 months and median OS was 24.7 months.
• Patients achieving partial response or stable disease had significantly longer OS than those with progressive disease.
• Intervention before progression and prior tumor control (≥12 months) independently predicted OS > 24 months.

Conclusions:

• HD-IFO can provide durable disease control in select sarcoma patients.
• Sustained prior tumor control and early intervention are crucial for long-term outcomes with HD-IFO therapy.